摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-ethyl-1-iodo-8-[2-(2,3,5-trifluorophenyl)ethyl]-5,6-dihydro-8H-imidazo[1,5-a]pyrazine-7-carboxylic acid tert-butyl ester | 1036398-24-9

中文名称
——
中文别名
——
英文名称
3-ethyl-1-iodo-8-[2-(2,3,5-trifluorophenyl)ethyl]-5,6-dihydro-8H-imidazo[1,5-a]pyrazine-7-carboxylic acid tert-butyl ester
英文别名
tert-butyl 3-ethyl-1-iodo-8-[2-(2,3,5-trifluorophenyl)ethyl]-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-7-carboxylate
3-ethyl-1-iodo-8-[2-(2,3,5-trifluorophenyl)ethyl]-5,6-dihydro-8H-imidazo[1,5-a]pyrazine-7-carboxylic acid tert-butyl ester化学式
CAS
1036398-24-9
化学式
C21H25F3IN3O2
mdl
——
分子量
535.348
InChiKey
RFLFIKVUTWNAEK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    30
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    47.4
  • 氢给体数:
    0
  • 氢受体数:
    6

文献信息

  • 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES
    申请人:Aissaoui Hamed
    公开号:US20100093740A1
    公开(公告)日:2010-04-15
    The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I), wherein X represents CH 2 or O; R 1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R 2 represents (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 2-4 )alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR 5 R 6 or cyclopropyl; R 3 represents (C 1-4 )alkyl, (C 1-4 )alkoxy-methyl or halogen; R 4 represents (C 1-4 )alkyl; R 5 represents hydrogen or (C 1-4 )alkyl; and R 6 represents hydrogen or (C 1-4 )alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
    本发明涉及公式(I)的5,6,7,8-四氢咪唑[1,5-a]吡嗪生物,其中X代表CH2或O; R1代表苯基,该基团独立地单取代、双取代或三取代,其中取代基独立地选自由(C1-4)烷基,(C1-4)烷氧基,卤素,基,三甲氧基和三甲基的群组; R2代表(C1-4)烷基,(C1-4)烷氧基,(C2-4)烯基,卤素,基,羟甲基,三甲基,C(O)NR5R6或环丙基; R3代表(C1-4)烷基,(C1-4)烷氧甲基或卤素; R4代表(C1-4)烷基; R5代表氢或(C1-4)烷基; R6代表氢或(C1-4)烷基。本发明还涉及这种化合物的药学上可接受的盐;以及将这种化合物用作药物的用途;特别是作为促进睡眠激素受体拮抗剂。
  • US8188082B2
    申请人:——
    公开号:US8188082B2
    公开(公告)日:2012-05-29
  • [EN] 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 5,6,7,8-TÉTRAHYDRO-IMIDAZO[1,5-A]PYRAZINE
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2008078291A1
    公开(公告)日:2008-07-03
    [EN] The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
    [FR] L'invention porte sur des dérivés de 5,6,7,8-tétrahydro-imidazo[1,5-a]pyrazine de formule (1), dans laquelle X représente CH2 ou O ; R1 représente un groupe phényle, lequel groupe est indépendamment mono-, di- ou tri- substitué, les substituants étant indépendamment choisis dans le groupe constitué par alkyle en C1-C4, alcoxy en C1-C4, halogène, cyano, trifluorométhoxy et trifluorométhyle ; R2 représente alkyle en C1-C4, alcoxy en C1-C4, alcényle en C2-C4, halogène, cyano, hydroxyméthyle, trifluorométhyle, C(O)NR5R6ou cyclopropyle ; R3 représente alkyle en C1-C4, alcoxy en C1-C4-méthyle, ou halogène ; R4représente alkyle en C1-C4 ; R5 représente hydrogène ou alkyle en C1-C4 ; et R6 représente hydrogène ou alkyle en C1-C4. L'invention porte également sur des sels pharmaceutiquement acceptables de tels composés ; et sur l'utilisation de tels composés en tant que médicaments, notamment en tant qu'antagonistes du récepteur de l'orexine.
查看更多

同类化合物

奥格列汀 吡唑并[3,4-a]吡咯里嗪 叔丁基3'-氨基-1',4'-二氢-5'H-螺[环丁烷-1,6'-吡咯并[3,4-C]吡唑]-5'-羧酸酯 5-苄基-1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-羧酸乙酯 5-甲基-1H,4H,5H,6H-吡咯并[3,4-C]吡唑 5-叔丁基3-乙基4,6-二氢吡咯并[3,4-c]吡唑-3,5(1h)-二羧酸 5-叔丁基1-乙基3-氨基-3A,4,6,6A-四氢吡咯并[3,4-C]吡唑-1,5-二甲酯 5-BOC-3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-1-甲酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑-2-羧酸乙酯 5,6-二氢-4H-吡咯并[1,2-b]吡唑 5,6-二氢-4H-吡咯并[1,2-B]吡唑-3-羧酸 5,6-二氢-4H-吡咯并[1,2-B]吡唑-3-甲醛 5,6-二氢-4H-吡咯并[1,2-B]吡唑-2-羧酸 5,6-二氢-3-羟基-4H-吡咯并[1,2-c][1,2,3]恶二唑-7-鎓内盐 4a,6c-二氮杂环丁[a]环戊二烯并[Cd]并环戊二烯 4,6-二氢吡咯并[3,4-C]吡唑-3,5(1H)-二甲酸5-叔丁酯 4,6-二氢-1H-吡咯[3,4-C]吡唑-5-甲酸丁酯 3-甲基-1H,4H,5H,6H叔丁基吡咯并[3,4-c]吡唑-5-羧酸酯 3-甲基-1,4,5,6-四氢-吡咯并[3,4-c]吡唑 3-溴-5,6-二氢-4H-吡咯并[1,2-b]吡唑 3-氨基-6-乙基-4,6-二氢吡咯并[3,4-C]吡唑-5(1H)-羧酸叔丁酯 3-氨基-6,6-二甲基-4,6-二氢吡咯并[3,4-C]吡唑-5(2H)-羧酸叔丁酯 3-氨基-6,6-二甲基- 吡咯并[3,4-c]吡唑-2,5(4H,6H)-二羧酸 5-(1,1-二甲基乙基) 2-乙酯 3-氨基-5-叔丁氧羰基-吡咯并[3,4-C]吡唑 3-氨基-4,6-二氢吡咯并[3,4-C]吡唑-5-甲酸叔丁酯 3-氨基-4,6-二氢-6,6-二甲基-吡咯并[3,4-c]吡唑-1,5-二甲酸 5-叔丁基 1-乙基酯 3-(4,4,5,5-四甲基-1,3,2-二氧杂硼杂环戊烷-2-基)-5,6-二氢-4H-吡咯并(1,2-B)吡唑 2-甲基-2-丙基3'-氨基-1',4'-二氢-5'H-螺[环丙烷-1,6'-吡咯并[3,4-c]吡唑]-5'-羧酸酯 2-甲基-2,4,5,6-四氢吡咯并[3,4-C]吡唑二盐酸盐 2-(甲基磺酰基)-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-羧酸叔丁酯 2,4,5,6-四氢-2-(甲基磺酰基)-吡咯并[3,4-c]吡唑 2,3-二氮杂三环[5.2.1.02,6]癸-1(9),3,5,7-四烯 1-甲基-1,4,5,6-四氢吡咯并[3,4-c]吡唑盐酸盐 1-(4-四氢吡喃基)-1,4,5,6-四氢吡咯并[3,4-C]吡唑盐酸盐 1-(3-氨基-4,5-二氢-1H-吡唑-1-基)-1-丙酮 1-(3-氨基-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-基)乙酮 1,4,5,6-四氢吡咯并[3,4-c]吡唑-3-胺 1,4,5,6-四氢吡咯并[3,4-C]吡唑 1,4,5,6-四氢吡咯并-[3,4-c]-吡唑双盐酸盐 1,4,5,6-四氢-1-甲基吡咯并[3,4-C]吡唑 (S)-3-氨基-N-(2-(二甲基氨基)-1-苯基乙基)-6,6-二甲基-4,6-二氢吡咯并[3 (9CI)-2,4,5,6-四氢-2-甲基-吡咯并[3,4-c]吡唑 2-(1-imidazolylcarbonylamino)-6-[2(R),6-dimethylheptyl]-4[1H]-pyrimidinone ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-(1-(trifluoromethyl)cyclopropanecarboxamido)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate 3-[(cyclobutylcarbonyl)amino]-N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carboxamide ethyl 5-(chlorocarbonyl)-6,6-dimethyl-3-(1-(trifluoromethyl)cyclobutanecarboxamido)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate 4-Methoxy-6,7-dimethyl-3,4-dihydro-pteridine; hydrochloride 5-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-2-methyl-phenyl)-3-isopropyl-2-(2-methyl-thiazol-4-ylmethyl)-4,5-dihydro-2H-pyrrolo[3,4-c]pyrazol-6-one 4-(4-chloro-2-methyl-phenyl)-5-(5-chloro-2-methyl-phenyl)-3-isopropyl-2-(4-methyl-piperazine-1-carbonyl)-4,5-dihydro-2H-pyrrolo[3,4-c]pyrazol-6-one 4-(4-chloro-2-methyl-phenyl)-5-(5-chloro-2-methyl-phenyl)-2-(2,3-dihydroxy-propyl)-3-isopropyl-4,5-dihydro-2H-pyrrolo[3,4-c]pyrazol-6-one